Skip to main content

14-06-2010 | Diabetes | Article

NICE recommends liraglutide for treating some people with Type 2 diabetes


NICE report

MedWire News: The National Institute for Health and Clinical Excellence (NICE) in the UK has recommended treatment with the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide for some patients with Type 2 diabetes in a preliminary draft guidance document.

“The incidence of Type 2 diabetes is on the increase in England and Wales – and sadly so too are the complications of the disease,” said NICE spokesperson Carole Longson.

“We are pleased, therefore, to recommend liraglutide 1.2 mg daily as a clinically and cost effective treatment option as part of both dual and triple therapy regimens for some patients with Type 2 diabetes mellitus under restrictions.”

This follows the recent approval of liraglutide by the US Food and Drug Administration with some stipulations, as reported by MedWire News.

NICE recommends that liraglutide 1.2 mg/day should be given to Type 2 diabetic patients requiring dual therapy to replace either metformin or a sulphonylurea due to being unable to tolerate either of these drugs.

As part of a triple therapy regimen, it suggests liraglutide 1.2 mg/day can be given in combination with metformin and a sulphonylurea or with metformin and a thiazolidinedione to patients whose glycated hemoglobin (HbA1c) is inadequately controlled, at levels of 7.5% or above. The guidance also recommends that these patients should have a body mass index (BMI) of 35 kg/m2 or above and specific psychological or medical problems linked to high body weight.

Other patients in whom liraglutide 1.2 mg/day is indicated include those with a BMI of 35 kg/m2 or below who would have severe occupational problems with taking insulin, or in whom weight loss would benefit any significant obesity-related comorbidities.

Notably, the NICE team does not recommend use of liraglutide at a dose of 1.8 mg/day as they say that the available evidence does not suggest a significant additional benefit with this higher dose.

NICE says that final guidance documents are likely to be published in October 2010.

MedWire ( is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010

By Helen Albert